


Novartis Financial Results - Q3 2018

Novartis delivered strong growth and innovation during the third quarter



Key Growth Drivers



Cosentyx[®] grew to USD 750 million (+37% cc) with strong volume growth across indications




Entresto[®] more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwide



Promacta[®]/Revolade[®] USD 295 million (+32% cc), Tafinlar[®] + Mekinist[®] USD 291 million (+33% cc) and Jakavi[®] USD 248 million (+27% cc) continued strong double-digit growth

Q3 at a glance

Strong innovation momentum continued



“We progressed our breakthrough medicines pipeline including our leading advanced therapy platforms in cell and gene and continued our strong operational performance.”



@VasNarasimhan
CEO, Novartis

Advanced Therapy Platforms

AVXS-101 simultaneous global submissions in US, EU and Japan² for SMA Type 1



More than 90% of children diagnosed with SMA Type 1, will die or need permanent ventilation support by the age of 2.⁴

¹ Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 56 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

² Initiated submission in mid-September, anticipate completion by year end.

³ Copaxone[®] is a registered trademark of Teva Pharmaceutical Industries Ltd.

⁴ Darras B.T., et al. Spinal Muscular Atrophy, Chapter 25 - Natural History of Spinal Muscular Atrophy, October 2016.